Introduction {#S0001}
============

GBC is the main pathological type of biliary tract cancers (BTC), accounting for 1.23% new cases and 1.45% mortalities of all cancers in the People\'s Republic of China.[@CIT0001] Detection of early-stage GBC remains difficult. GBC is usually discovered incidentally at surgery or pathologic examination at advanced stage. Therapeutic options for advanced GBC are limited and the outcome is poor. The 5-year survival rate was only 5% for stage III patients and 1% for stage IV patients.[@CIT0002] According to the latest National Comprehensive Cancer Network (NCCN) guidelines for hepatobiliary cancer, first-line therapies for metastatic GBC included chemotherapy regimens and pembrolizumab treatment for microsatellite instability high (MSI-H) patients. No standard therapeutic options were available as second or beyond lines of therapies for advanced GBC patients.

Immunotherapy such as programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors treatment, had emerged as prospective therapeutics in multiple solid tumors. Several clinical trials were conveyed in BTC as well and obtained promising results in second-line therapy, such as the KEYNOTE 028 trial, KEYNOTE 158 trial and one phase II trial of Nivolumab.[@CIT0003]--[@CIT0005] Objective response rate (ORR) of immunotherapy was only around 20% in unselected patients with malignant solid tumors.[@CIT0006] Population with immunotherapy-favoring biomarkers such as PD-L1 expression positive, tumor mutation burden (TMB) high and microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) may obtain better clinical response compared with biomarker-negative subpopulations.[@CIT0007] Nowadays, data of clinical trials of immunotherapies in Chinese GBC patients are insufficient. Potential predictors of drug efficacy are also in urgent need of further exploration. Herein, we report a recurrent metastatic GBC patient with strong PD-L1 expression (≥50%) who obtained significant response to Nivolumab treatment.

Case presentation {#S0002}
=================

In November, 2015, a 69-year-old female patient was admitted to Nanjing Second Hospital and received radical resection of gallbladder cancer. Postoperative pathology indicated a T3N0M0 adenocarcinoma with moderate differentiation ([Figure 1A](#F0001){ref-type="fig"}). The patient recovered well after surgery and received no anticancer regimens. Regular follow-up visits were performed. In May 2017, positron emission tomography/computed tomography (PET/CT) results revealed tumor recurrence with the right adrenal metastasis and local intrahepatic metastasis ([Figure 1B](#F0001){ref-type="fig"}). The patient was then admitted to our hospital, and the treatment plan, the curative effect and adverse reactions were evaluated through a multiple disciplinary team (MDT).Figure 1Pathology or PET/CT images of primary and recurrent tumor tissues. (**A**) Pathology of postoperative samples, indicating moderately differentiated adenocarcinoma. (**B**) PET/CT results indicating oligo metastasis within the liver and in the right adrenal gland.

From June 2017, this patient received radiotherapy (DT 60Gy/12f in tumor area and DT 30Gy/12f in prevention area) followed up by concurrent gemcitabine + capecitabine chemotherapy as first-line therapy. After six cycles of chemotherapy, the patient reached a best response of stable disease (SD). Progressive disease (PD) was observed in left kidney and lymph node in April 2018. Two cycles of GEMOX (gemcitabine combined with oxaliplatin) regimen chemotherapy was taken as second-line therapy since April 2018. Unfortunately, the disease progressed quickly with a new left hip metastasis. Third line palliative radiotherapy (total dose 30Gy/10f) was used for left hip lesions and disease progression was observed again with new occupancies in liver and lung in July, 2018.

To seek other potential therapeutic opportunities, the patient received next generation sequencing (NGS) analysis using a 381-gene panel (provide by 3D Medicines Inc.) and immunohistochemistry (IHC) detection of PD-L1 expression. NGS results indicated that the tumor mutation burden (TMB) was 4.03 Mutants/Mb ([Table 1](#T0001){ref-type="table"}) and the microsatellite state was stable ([Table 1](#T0001){ref-type="table"}). IHC results indicated that the PD-L1 expression was 50% ([Figure 2](#F0002){ref-type="fig"}). TMB was defined as the number of somatic mutations per million bases in sequenced coding region. No other immunotherapy-related biomarkers were identified ([Table 2](#T0002){ref-type="table"}).Table 1Tumor mutation burden and microsatellite instability stateItemResultTMB (mutants/Mb)4.03MicrosatelliteStable Table 2Gene mutation listGene nameMutation*ATMp*.H1384Rfs\*3 Exon28*ARID1Ap*.A360Efs\*37 Exon1*EPHA2p*.M689Ifs\*2*UGT1A1p*.G71R c.211G\>A rs4148323 \*6*CYP2C19p*.P227P c.681G\>A rs4244285 \*2 Figure 2The patient with PD-L1 strong expression. Immunohistochemical staining of PD-L1 expression. The PD-L1 expression of the patient sample was 50%. PD-L1 was stained by VENTANA PD-L1 (SP263) Assay kit following the manufacturer\'s instructions. Positive control and negative control were provided by the kit, indicating PD-L1-expressing and non-PD-L1-expressing tissues, respectively. The "patient sample" was paraffin section of FFPE-embedded tumor sample.

Combination of radiotherapy and immunotherapy was then considered. Hypofractionated helical tomotherapy (total dose 60Gy/12f) was administrated to new metastases in the left lobe of the liver, and the patient has received four times of nivolumab therapy (120 mg, every 2 weeks) since September 2018. Metastases in retroperitoneal lymph nodes, left hip and lung all disappeared. Lesions in liver and left kidney received significant response to the treatment ([Figure 3](#F0003){ref-type="fig"}). The patient was still alive with a progression free survival (PFS) exceeding 6 months, and no adverse events were observed.Figure 3Computed tomography scan shows different lesions in lung, lymph node, left kidney, liver, and left hip during immunotherapy. (**A**) Lesions before immunotherapy are indicated by arrows. (**B**) Lesions after immunotherapy are indicated by arrows.

Discussion and conclusion {#S0003}
=========================

In this case, the patient with strong PD-L1 expression (≥50%) responded deeply to nivolumab immunotherapy after failure of multiple lines of therapies. To our knowledge, this is the first case presenting significant nivolumab response in an advanced GBC patient in the People\'s Republic of China.

PD-L1 expression has been considered as an immunotherapy biomarker in NSCLC, melanoma and many other solid tumors, and the expression level was associated with efficacy.[@CIT0006],[@CIT0008] In KEYNOTE 028 trial, PD-L1+ (≥1%) BTC patients reached an ORR of 17.4%.[@CIT0003] In KEYNOTE 158 trial, the ORR was 6.6% vs 2.9% in PD-L1+ (≥1%) vs PD-L1- (\<1%) BTC patients, respectively. In one phase II trial, nivolumab reached an ORR of 18.5%, irrespective of PD-L1 expression, however, subgroup analysis of different PD-L1 expression stratifications were not performed.[@CIT0004] Based on the three clinical trials mentioned above, whether PD-L1 expression is a biomarker for BTC immunotherapy is still uncertain, especially for nivolumab. In our case, the patient bore strong PD-L1 expression (≥50%) and obtained significant benefit from nivolumab treatment, which might indicate that PD-L1 expression could be a potential biomarker in GBC immunotherapy.

According to a secondary analysis of KEYNOTE 001 trial and other clinical evidences, previous radiotherapy (RT) may enhance PFS and overall survival (OS) in patients receiving immunotherapy.[@CIT0009],[@CIT0010] This is presumably because tumor cells damaged by RT could release antigens that could serve as adaptive immune response targets and enhance immune response. In this case, we applied hypofractionated radiotherapy on liver lesions, which indeed lead to enhanced immunogenicity and better immunotherapy response. This synergetic effect between RT and immunotherapy might also contribute to the significant response to nivolumab in this patient.

In clinical trial CHECKMATE 026 and CHECKMATE 227, compared with TMB-middle and TMB-low patients, TMB-high subpopulation received better clinical outcomes.[@CIT0011],[@CIT0012] MSI-H/dMMR, another potential biomarker of immunotherapy, showed a significantly higher response vs MSS (microsatellite stable) or pMMR solid tumors.[@CIT0013] In our case, the TMB was merely middle and the microsatellites were stable, thus we speculated that strong PD-L1 expression is the main reason for the deep response.

To our knowledge, this is the first case describing a strong PD-L1 positive GBC patient who received a significant response to nivolumab treatment. This case indicated that PD-L1- or PD-1-based immunotherapies may bring new treatments for recurrent metastatic GBC patients, especially in those with strong PD-L1 expression. Still, more studies are needed to validate this finding.
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